The treatment of breast and prostate cancers is based on immunohistochemical analysis of well-known prognostic markers such as ER, PR, Ki67, cerb2 (Figure 1), or PSA [25, 26]. The gene discussed is ERBB2; the disease is prostate carcinoma.